.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,486,942

« Back to Dashboard

Details for Patent: 8,486,942

Title:Modulators of pharmacokinetic properties of therapeutics
Abstract: The present application provides for a compound of Formula IV, ##STR00001## or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
Inventor(s): Desai; Manoj C. (Pleasant Hill, CA), Hong; Allen Y. (Pasadena, CA), Hui; Hon C. (San Mateo, CA), Liu; Hongtao (Cupertino, CA), Vivian; Randall W. (San Mateo, CA), Xu; Lianhong (Palo Alto, CA)
Assignee: Gilead Sciencs, Inc. (Foster City, CA)
Filing Date:Nov 21, 2011
Application Number:13/301,642
Claims:1. A method for treating an HCV infection in a patient in need thereof, comprising administering to the patient an amount of a compound ##STR00291## or a pharmaceutically acceptable salt-thereof, which is effective to inhibit cytochrome P450 monoxygenase in the patient, in combination with a therapeutically effective amount of one or more therapeutic agents which are metabolized by cytochrome P450 monoxygenase and are selected from the group consisting of interferons, ribavirin, taribavirin, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors, other drugs for treating HCV, and mixtures thereof.

2. The method of claim 1, wherein: (1) the interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha, feron, reaferon, intermax alpha, r-IFN-beta, oral interferon alpha, IFNalpha-2b XL, AVI-005, and Pegylated IFN-beta; (2) the NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433; (3) the NS3 protease inhibitor are selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN-191; (4) the alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B; (5) the hepatoprotectants are selected from the group consisting of IDN-6556, ME 3738, and LB-84451; (6) the non-nucleoside inhibitors are selected from the group consisting of A-831 and A-689; and (7) the other drugs for treating HCV are selected from the group consisting of zadaxin, nitazoxanide, BIVN-401, PYN-17, KPE02003002, CPG-10101, KRN-7000, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).

3. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha, feron, reaferon, intermax alpha, r-IFN-beta, oral interferon alpha, IFNalpha-2b XL, AVI-005, and Pegylated IFN-beta.

4. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433.

5. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN-191.

6. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of MX-3253 (celgosivir) and UT-231B.

7. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of IDN-6556, ME 3738, and LB-84451.

8. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting A-831 and A-689.

9. The method of claim 1, wherein the one or more additional therapeutic agents are selected from the group consisting of zadaxin, nitazoxanide, BIVN-401, PYN-17, KPE02003002, CPG-10101, KRN-7000, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc